Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Abida, Wassim; Campbell, David; Patnaik, Akash; Shapiro, Jeremy; Sautois, Brieuc; J. Vogelzang, Nicholas; Voog, Éric; H. Bryce, Alan; McDermott, Ray; Ricci, Francesco; Rowe, Julie; Zhang, Jingsong; M. Piulats, Josep; Fizazi, Karim; S. Merseburger, Axel; S. Higano, Celestia; E. Krieger, Laurence; J. Ryan, Charles; Y. Feng, Felix; D. Simmons, Andrew; Loehr, Andrea; Despain, Darrin; Dowson, Melanie; Green, Foad; P. Watkins, Simon; Golsorkhi, Tony; Chowdhury, Simon

doi:10.1158/1078-0432.ccr-20-0394

Public

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Published in Clinical Cancer Research • Feb 21, 2020

Authors:

Wassim Abida

David Campbell

Akash Patnaik

Abstract

Abstract Purpose: Genomic alterations in DNA damage repair (DDR) genes other than BRCA may confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate cancer (mCRPC). To test this hypothesis, the phase II TRITON2 study of rucaparib included patients with mCRPC and del...

Subject

CHEK2

Prostate cancer

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!